MacroGenics (MGNX)
(Delayed Data from NSDQ)
$4.14 USD
+0.40 (10.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.13 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.14 USD
+0.40 (10.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.13 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Zacks News
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
by Zacks Equity Research
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
by Zacks Equity Research
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
by Zacks Equity Research
Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
by Zacks Equity Research
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
by Zacks Equity Research
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
by Zacks Equity Research
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
What's in Store for GW Pharma (GWPH) This Earnings Season?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 37.21% and 236.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
MacroGenics has been struggling lately, but the selling pressure may be coming to an end soon.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 14.17% and 327.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.